Pure Global AI
NCT05940558Recruiting

Safety and Efficacy of MBF-118 in Patients With Crohn Disease

A Phase IIa, Open Label, Single-centre Study to Assess the Initial Antifibrotic Efficacy, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of MBF-118 in Crohn's Disease Patients With Stenosis
Medibiofarma S.L.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Crohn Disease
Drug/Device/Intervention
MBF-018 oral capsules
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Medibiofarma S.L.
Location
Santiago de Compostela, Spain
Timeline & enrollment
Phase
Phase 2
Start date
Apr 12, 2023
End date
Apr 01, 2024
Enrollment
10 participants
Primary outcome

Number of Adverse events

Summary

This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety
 and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on
 top of standard of care.

ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease of small intestineCrohn disease [regional enteritis]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05940558
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05940558 through Pure Global AI's free database. This Phase 2 trial is sponsored by Medibiofarma S.L. and is currently Recruiting. The study focuses on Crohn Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.